Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment

Cécile Ortholan, Jérôme Durivault, Jean Michel Hannoun-Levi, Mélanie Guyot, Christine Bourcier, Damien Ambrosetti, Stephen Safe, Gilles Pags

Research output: Contribution to journalArticle

28 Scopus citations

Fingerprint Dive into the research topics of 'Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences